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Objective: Osteoarthritis (OA) is a heterogeneous disease with symptom 
progression at the foot unclear. This study investigated the symptomatic course of 
three pre-defined foot OA phenotypes over an 18-month period. 
Methods: The Clinical Assessment Study of the Foot (CASF) is a community-based 
cohort of adults aged ≥50 years in North Staffordshire, UK. Participants who reported 
foot pain in a postal health survey and underwent radiographic assessment were 
mailed an 18-month follow-up survey. Changes in descriptive and symptomatic 
outcomes over 18 months were compared across the three phenotypes to determine 
within-phenotype changes and between-phenotype differences. 
Results: Of 533 participants at baseline, 478 (89.7%) responded at 18 months. All 
three phenotypes showed small within-phenotype improvements in mean foot pain 
severity (scale from 0=no pain to 10=worst pain): no or minimal foot OA (18-month 
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4.0; mean change -1.15 [95% CI -1.46,-0.83]), isolated first metatarsophalangeal 
joint (MTPJ) OA (18-month 4.1; mean change -0.60 [95% CI -1.11,-0.10]) and 
polyarticular foot OA (18-month 5.1; mean change -0.77 [95% CI -1.42,-0.12]). The 
isolated first MTPJ OA phenotype had an increased likelihood of hallux valgus in the 
left foot (adjusted odds ratio 2.96 [95% CI 1.23,7.12]) compared to the no or minimal 
foot OA phenotype. 
Conclusion: Three foot OA phenotypes showed few descriptive or symptomatic 
changes over 18 months. Future clinical trials should consider that people recruited 
with mild-to-moderate symptomatic foot OA appear likely to remain relatively stable 
with usual care. Longer-term follow-up using additional time-points is required to 
describe further the natural history of foot OA. 
 
Significance and Innovations 
 This is the first investigation of symptomatic change over time in patients with 
radiographically defined foot OA.  
 Despite varying degrees of radiographic severity across phenotypes, few 
symptomatic changes over 18 months were observed within or between 
phenotypes. 
 Future clinical trials should consider that people recruited with mild-to-
moderate symptomatic foot OA appear likely to remain relatively stable with 
usual care over 18 months. 
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Introduction  
Osteoarthritis (OA) is a multifactorial synovial joint disease, characterised by 
emerging clinical and structural sub-phenotypes, that once fully explained may 
facilitate more targeted treatment approaches [1]. Most recently, epidemiological 
observations of OA have extended to the foot, with symptomatic radiographic foot 
OA estimated to affect one in six adults aged 50 years and over [2]. Despite recent 
evidence supporting the contribution of OA to foot pain, distinct progressive and non-
progressive symptomatic courses observed at the knee [3], hip [4] and hand [5] have 
yet to be investigated at the foot. Although only one prospective study has examined 
the progression of radiographic foot OA [6], the progression of symptoms among 
individuals with symptomatic radiographic foot OA remains unclear.  
Using latent class analysis, we have recently identified three distinct foot OA 
phenotypes based on the radiographic scoring of five foot joints (first 
metatarsophalangeal joint (MTPJ), first and second cuneometatarsal joint, navicular 
first cuneiform joint and talonavicular joint) [7]. These include an isolated first MTPJ 
OA phenotype and a polyarticular foot OA phenotype; both found to be distinct from 
a phenotype with no or minimal foot OA [7]. Cross-sectionally, the polyarticular foot 
OA phenotype demonstrated more pain and functional limitation than the other two 
phenotypes, as well as stronger associations with female gender, higher body mass 
index (BMI) and nodal hand OA [7]. The present analyses extend our investigations 
of these distinctive foot OA phenotypes to describe their natural history over time. 
Specifically, the aim of this study was to investigate the symptomatic course of these 
pre-defined foot OA phenotypes over an 18-month period. Eighteen months is 
sufficient to detect a clinically meaningful change in OA if present [1]. We 
hypothesised that symptoms would be relatively stable over 18 months, but that the 
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polyarticular foot OA phenotype would demonstrate a trend for worsening of 
symptoms. 
 
Methods 
Design and study population   
Data were used from the Clinical Assessment Study of the Foot (CASF), which is a 
community-based cohort of adults aged 50 years and older, registered with one of 
four general practices in North Staffordshire, UK. A full protocol has been reported 
previously [8]. Briefly, participants who reported foot pain in the previous 12 months 
in a baseline postal health survey were invited to attend a research clinic where they 
underwent weight-bearing anterior-posterior and lateral radiographs of both feet. 
Participants with no foot x-rays or an inflammatory arthropathy (non-specific 
inflammatory arthritis, rheumatoid arthritis or psoriatic arthritis), as identified from 
medical records or clinical radiology reports, were excluded from the analyses. A 
follow-up survey was mailed to participants 18 months after clinic attendance. 
Participants who did not respond to the 18-month follow-up survey after two weeks 
were sent a reminder postcard. Participants who did not respond after four weeks 
from initial mailing were sent a repeat survey. Non-responders to the repeat survey 
were further invited to complete a shortened minimal data collection (MDC) 
questionnaire designed to capture key outcome data. MDC was completed by 
telephone, or if unavailable, by mail [8]. Ethical approval was obtained from Coventry 
Research Ethics Committee (REC reference number: 10/H1210/5) and all 
participants provided written informed consent. For this analysis, we retained 
participants in their previously assigned baseline foot OA phenotypes based on their 
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radiographic characteristics: no or minimal foot OA, isolated first MTPJ OA and 
polyarticular foot OA [7]. 
 
Descriptive and symptomatic outcomes 
Data collected from baseline only included age, gender and BMI (calculated from 
height and weight measured at the baseline research clinic) [8]. Data collected from 
both the baseline health survey and 18-month follow-up survey included: foot pain 
severity in the previous month using a 0-10 Numerical Rating Scale (NRS), anchored 
at 0= no pain and 10= pain as bad as could be; Rasch-transformed Manchester Foot 
Pain and Disability Index (MFPDI), which derived an interval-level scale from the 
original three-part ordinal MFPDI responses [9, 10]; Short Form-12 (SF-12) physical 
and mental component summary scores (PCS and MCS, respectively) [11]; Hospital 
Anxiety and Depression Scale (HADS) [12]; frequent foot pain in the previous month; 
dissatisfaction with foot symptoms persisting; presence of hip and/ or knee pain in 
the previous year; and hallux valgus. Frequent foot pain was categorised as 
participants reporting pain or aching or stiffness in their feet on “most days” or “all 
days” in the previous month. Dissatisfaction with foot symptoms persisting was 
categorised as participants being “very dissatisfied” or “somewhat dissatisfied” with 
spending the rest of their lives with their current foot symptoms. Hallux valgus was 
categorised as unilateral or bilateral using a validated self-report line-drawing 
instrument [13]. Participants chose one of five line-drawings which best depicted the 
appearance of each foot. Each line-drawing sequentially increased the hallux valgus 
angle by 15⁰ ; with the three more severe illustrations categorised as hallux valgus 
[13].  
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Additional data collected at 18-month follow-up only included: perceived global 
change in foot pain over 18 months since baseline clinic attendance, which was 
categorised as “improved”, “unchanged”, and “deteriorated”; foot injury and foot 
operation in the previous 18 months; and use of services or treatments because of 
foot pain in the previous 18 months. Services or treatments included at least one of 
the following: physiotherapy, hospital specialist, podiatrist, chiropodist, acupuncture, 
osteopath or chiropractor, drugs on prescription, foot operation, foot injection, or 
general practitioner (family doctor).   
Symptomatic outcomes contained in both the full survey and MDC included: 
perceived global change in foot pain, MFPDI pain and function scores, and frequent 
foot pain in the previous month. 
 
Statistical analysis 
Descriptive and symptomatic outcomes were analysed with baseline and 18-month 
data to investigate within-phenotype changes and between-phenotype differences. 
Statistical significance was determined as p<0.05. Changes over time within-
phenotypes were examined using McNemar’s test for dichotomous variables and 
paired t-test for continuous variables. Between-phenotypes differences were 
examined using binary logistic regression for dichotomous outcomes and linear 
regression for continuous outcomes. The no or minimal foot OA phenotype was used 
as the reference category for the regression analyses. Estimates were adjusted for 
baseline scores and the following potenial confounders due to observed between-
phenotype differences seen at baseline: age, gender and BMI [7]. Using data at 18 
months only, differences between the three phenotypes at 18 months were 
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examined using a Chi-squared test. All analyses were conducted using SPSS 
Version 21 (IBM Corporation, Armonk, NY, USA). 
 
Results 
Study population  
Of the 533 participants at baseline, after exclusions for no foot x-rays (n=3) and 
inflammatory arthritis (n=24), 478 returned the 18-month follow-up survey (89.7% 
response), of which 307 (64.2%) had no or minimal foot OA, 101 (21.1%) isolated 
first MTPJ OA and 70 (14.6%) polyarticular foot OA. Participants who returned the 
follow-up survey were generally similar to those lost to follow-up. However, those lost 
to follow-up were more likely to have dissatisfaction with foot symptoms persisting, 
hip pain and knee pain (Supplementary Table 1). Reasons for loss to follow-up are 
outlined in Supplementary Figure 1. 
 
Within-phenotype changes 
Overall, all three phenotypes showed small mean and percentage changes between 
baseline and 18 months (Table 1). Small but statistically significant improvements 
were observed for mean foot pain severity within all three phenotypes: no or minimal 
foot OA (18-month 4.0; mean change -1.15 [95% confidence interval (CI) -1.46, -
0.83]), isolated first MTPJ OA (18-month 4.1; mean change -0.60 [95% CI -1.11, -
0.10]) and polyarticular foot OA (18-month 5.1; mean change -0.77 [95% CI -1.42, -
0.12]). Additionally, individuals with no or minimal foot OA showed a statistically 
significant improvement in mean Rasch-transformed MFPDI pain score (18-month -
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0.6; mean change -0.29 [95% CI -0.46, -0.12]), mean SF-12 PCS score (18-month 
40.9; mean change +1.71 [95% CI 0.66, 2.75]), mean HADS anxiety score (18-
month 6.5; mean change -0.58 [95% CI -0.96, -0.20]) and the proportion of 
participants reporting frequent foot pain in the previous month (18-month 39.1%; 
change -10.7%). However, a greater proportion of participants in the no or minimal 
foot OA phenotype reported hip pain at 18 months than at baseline (18-month 
58.8%; change +5.9%). Individuals in the isolated first MTPJ OA phenotype reported 
dissatisfaction with foot symptoms persisting less frequently (18-month 30.5%; 
change -12.7%). The polyarticular foot OA phenotype showed statistically significant 
improvement in the mean HADS anxiety scores (18-month 6.5; mean change -0.72 
[95% CI -1.37, -0.08]). 
 
Between-phenotype differences 
Following adjustment for baseline scores, age, gender and BMI, generally small 
between-phenotype differences were seen over 18 months between the isolated first 
MTPJ OA and polyarticular foot OA phenotypes in relation to the reference category 
of the no or minimal foot OA phenotype (Table 2). The isolated first MTPJ OA 
phenotype was significantly more likely than the no or minimal foot OA phenotype to 
report unilateral hallux valgus in the left foot at 18 months (adjusted odds ratio 2.96; 
95% CI 1.23, 7.12).  
There were no statistically significant differences in perceived global change in foot 
pain or foot injuries incurred over 18 months between the foot OA phenotypes (Table 
3). However, a higher proportion (40.6%) of individuals in the polyarticular foot OA 
phenotype perceived that their foot pain had deteriorated compared to the first MTPJ 
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OA (27.0%) and no or minimal foot OA (27.9%) phenotypes. Approximately half the 
participants in each phenotype reported using a service or treatment for foot pain in 
the preceding 18 months. The proportion of participants reporting a foot operation 
during this period was very low (≤4.0%) for each phenotype.  
 
Discussion  
This study investigated the symptomatic course of three foot OA phenotypes over an 
18-month period. The main finding from this study was a general trend for slight 
improvements of health outcomes across all three foot OA phenotypes; with small 
but statistically significant reductions in foot pain severity in particular. Few between-
phenotype differences occurred over the 18-month period.   
In absolute terms, the reduction in pain severity across the three phenotypes was 
small (range 0.60– 1.15 NRS points), with all observed values under the accepted 
two-point reduction threshold applied to denote a clinically important difference in 
musculoskeletal pain [14]. Therefore, whilst observed changes in pain severity were 
statistically significant, they are unlikely to represent a clinically meaningful change 
for the participants. Furthermore, it is impossible to know with certainty whether and 
how improvements in foot pain severity correspond to sites of radiographic OA. 
Potential explanations for the observed reduction in pain may include increased 
awareness and prioritisation of foot pain after enrolment into the CASF study and 
regression to the mean. However, those with polyarticular foot OA had a higher 
proportion of participants that indicated deterioration in their global foot pain over 18 
months compared to the other phenotypes, albeit not significantly.  
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A trend of pain improvement at the first follow-up measurement is consistent with 
improvements in knee pain trajectories observed in adults with knee OA [3]. 
Following initial improvement from baseline, Collins et al. found that all knee pain 
trajectories remained relatively stable over the remaining five-year follow-up [3]. With 
only one follow-up time point in this study, it is uncertain whether the small changes 
in foot pain observed over 18 months are representative of the long-term clinical 
course of foot OA. Furthermore, pain trajectories are not always stable and may 
fluctuate over time, as previously observed for hip OA [4]. Our findings suggest mild-
to-moderate symptomatic foot OA progression is unlikely to be rapid over 18 months 
and management can be monitored in primary care without the need for routine 
referral to secondary care. Future research directed at identifying individuals most 
likely to have unfavourable prognosis, who would benefit from timely onward referral, 
would appear important. 
Between-phenotype comparisons identified little difference between the foot OA 
phenotypes in relation to their descriptive and symptomatic characteristics. Following 
adjustment for potential confounders, there was only one statistically significant 
between-phenotype difference: an increased likelihood of unilateral hallux valgus in 
the left foot for the isolated first MTPJ OA phenotype compared to the no or minimal 
foot OA phenotype. Comparison of actual numbers revealed that overall there were 
six new cases of unilateral hallux valgus in the left foot for the isolated first MTPJ OA 
phenotype, and seven fewer cases for the no or minimal foot OA phenotype. Whilst 
the identification of new cases over an 18-month period is a possibility, the 
progressive nature of hallux valgus makes an observed reduction in severity appear 
implausible. The number of reported foot operations and new bilateral hallux valgus 
cases, suggesting progression from unilateral to bilateral hallux valgus, at 18 months 
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were insufficient to account for this observation. Misclassification of self-reported 
hallux valgus may therefore account for some of the reported changes over 18 
months, particularly when participants reported borderline hallux valgus. Despite the 
hallux valgus line drawing instrument previously demonstrating good reliability over a 
6-month period, [13] we did not assess reliability again at 18 months and it is 
plausible that this was lower than that previously reported. Indeed, the wide 95% CI 
for the odds ratio of the unilateral hallux valgus in the left foot reflects an imprecise 
estimate. Therefore, although these findings may indicate that the first MTPJ OA 
phenotype is a risk factor for development of unilateral hallux valgus in the left foot, 
the finding is possibly spurious and should be interpreted with caution. 
The data from this study were derived from CASF, which has a source population 
broadly representative of the British population, despite having a lower proportion of 
ethnic minorities [8]. By identifying participants from CASF with foot pain over the 
previous year, this study provides a sample broadly representative of the British 
population with foot pain. Additionally, there was a high retention of participants at 18 
months (89.7%). However, some limitations need to be considered. Firstly, 
participants were likely to have foot pain across multiple foot areas. Foot pain can 
lead to compensatory changes in gait and foot function, thus increasing the risk of 
pain at other foot areas [15]. Therefore, whether changes in reported foot pain 
severity related to the same pain sites from baseline to follow-up is uncertain. 
Secondly, participants lost to follow-up had a trend for being more dissatisfied with 
foot symptoms persisting, whilst also having more hip and knee pain (Supplementary 
Table 1). This suggests that participants lost to follow-up had more widespread joint 
pain. Although this is unlikely to have influenced the relative differences between the 
phenotypes, it may have resulted in an underestimation of absolute symptom 
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severity. Thirdly, participants were allocated to foot OA phenotypes at baseline; 
therefore, whether participants transitioned between phenotypes over time is 
uncertain.  
In conclusion, this is the first study to investigate symptomatic changes in patients 
with radiographic foot OA over time. Although findings suggest a general statistical 
trend for slight symptomatic improvement, this is unlikely to be clinically meaningful. 
Few between-phenotype differences were observed and a statistically significant 
finding of more prevalent unilateral hallux valgus in the isolated first MTPJ OA 
phenotype may be an artefact of misclassification. Future clinical trials should 
consider that people recruited with mild-to-moderate symptomatic foot OA appear 
likely to remain relatively stable with usual care. Additional follow-up over a longer 
time period is needed to understand further the natural history of foot OA and 
whether the course of foot symptoms differs between different phenotypes.  
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List of Tables 
Table 1  Changes in selected outcomes from baseline to 18 months for the three foot osteoarthritis phenotypes. 
 No or minimal foot OA phenotype Isolated first MTPJ OA phenotype Polyarticular foot OA phenotype 
 
18-month 
score: mean 
(SD) 
Mean change  
(95% CI) 
18-month 
score:      
mean (SD) 
Mean change  
(95% CI) 
18-month 
score: 
mean (SD) 
Mean change  
(95% CI) 
Foot pain severity rating (0-10 Numeric Rating 
Scale) in the previous month 
a
 
4.0 (2.8) -1.15 (-1.46, -0.83) 4.1 (2.8) 
-0.60 (-1.11, -
0.10) 
5.1 (2.5) -0.77 (-1.42, -0.12) 
Rasch-transformed MFPDI pain score -0.6 (1.7) -0.29 (-0.46, -0.12) -0.8 (1.6) -0.22 (-0.51, 0.07) 0.1 (1.4) -0.12 (-0.40, 0.16) 
Rasch-transformed MFPDI function score -0.9 (2.1) -0.03 (-0.20, 0.14) -1.0 (2.1) +0.01 (-0.30, 0.31) 0.2 (2.1) +0.07 (-0.27, 0.41) 
SF-12 PCS score 40.9 (12.2) +1.71 (0.66, 2.75) 40.8 (11.1) -0.34 (-2.29, 1.61) 37.6 (11.8) +1.12 (-0.98, 3.22) 
SF-12 MCS score 49.5 (10.7) +0.03 (-1.13, 1.19) 50.2 (10.6) -1.04 (-2.98, 0.90) 47.9 (11.9) -0.96 (-3.72, 1.79) 
HADS anxiety score 6.5 (4.3) -0.58 (-0.96, -0.20) 5.9 (4.2) -0.55 (-1.23, 0.13) 6.5 (3.8) -0.72 (-1.37, -0.08) 
HADS depression score 5.1 (3.8) -0.26 (-0.55, 0.35) 4.6 (3.6) -0.13 (-0.67, 0.41) 6.1 (3.8) -0.15 (-0.72, 0.41) 
 
18-month 
score: n (%) 
Change: %         
(P-value) 
18-month 
score: n (%) 
Change: %         
(P-value) 
18-month 
score: n (%) 
Change: %         
(P-value) 
Frequent foot pain in the previous month 
b 
116 (39.1) -10.7 (<0.01) 38 (38.0) -10.0 (0.1) 38 (55.9) -13.2 (0.12) 
Dissatisfaction with foot symptoms persisting 
c 
122 (40.9) -6.1 (0.08) 29 (30.5) -12.7 (0.04) 32 (48.5) -13.6 (0.12) 
Bilateral hallux valgus 
d 
49 (17.0) +0.7 (0.87) 27 (27.8) 0.0 (1.00) 22 (32.8) -6.0 (0.45) 
Unilateral hallux valgus 
d
 – left foot 21 (7.3) -2.4 (0.27) 12 (12.4) +6.2 (0.07) 8 (11.9) +1.5 (1.00) 
Unilateral hallux valgus 
d
 – right foot 39 (13.5) +0.7 (0.87) 9 (9.3) -1.0 (1.00) 7 (10.4) +2.9 (0.75) 
Hip pain in the previous year 171 (58.8) +5.9 (0.04) 60 (61.2) +7.1 (0.19) 45 (68.2) 0.0 (1.00) 
Knee pain in the previous year 218 (74.7) +2.4 (0.38) 77 (78.6) +5.1 (0.41) 55 (83.3) -6.1 (0.29) 
 
CI= confidence interval; HADS= Hospital Anxiety and Depression Scale (higher HADS score indicate worse psychiatric ratings); 
MCS= mental component summary; MFPDI= Manchester Foot Pain and Disability Index (higher MFPDI scores indicate higher 
pain/ function); MTPJ= metatarsophalangeal joint; OA= osteoarthritis; PCS= physical component summary; SD= standard 
deviation; SF-12= 12-Item Short-Form Health Survey (higher SF-12 PCS and MCS scores indicated better health); 
a
= The 
numeric rating scale included verbal anchors of “no pain” at 0 and “pain as bad as could be” at 10; b= defined as frequent pain, 
aching or stiffness on all or most days in the previous month; 
c
= defined as participants being very or somewhat dissatisfied with 
the foot symptoms persisting for the rest of their lives; 
d
= Hallux valgus was defined according to Roddy et al.’s [13] self-report 
instrument and dichotomised definition. Results with Bold text indicate that the result is statistically significant (p <0.05). 
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Table 2 Between-phenotype differences for the isolated first metatarsophalangeal 
joint osteoarthritis and polyarticular foot osteoarthritis phenotype at 18 months using 
the no or minimal foot osteoarthritis phenotype as the reference category. 
β= regression coefficient; CI= confidence interval; HADS= Hospital Anxiety and Depression Scale (higher HADS score 
indicate worse psychiatric ratings); MCS= mental component summary; MFPDI= Manchester Foot Pain and Disability 
Index (higher MFPDI scores indicate higher pain/ function); MTPJ= metatarsophalangeal joint; OA= osteoarthritis; OR= 
odds ratio; PCS= physical component summary; SD= standard deviation; SF-12= 12-Item Short-Form Health Survey 
(higher SF-12 PCS and MCS scores indicated better health); 
a= The numeric rating scale included verbal anchors of “no 
pain” at 0 and “pain as bad as could be” at 10; b= defined as frequent pain, aching or stiffness on all or most days in the 
previous month; 
c
= defined as participants being very or somewhat dissatisfied with the foot symptoms persisting for the 
rest of their lives; 
d
= Hallux valgus was defined according to Roddy et al.’s [13] self-report instrument and dichotomised 
definition; 
e
= includes adjustment for baseline scores, age, gender, and body mass index. Results with Bold text indicate 
that the result is statistically significant (p <0.05). 
 Isolated first MTPJ OA Polyarticular foot OA 
 Adjusted 
e
 β (95% CI) Adjusted 
e
 β (95% CI) 
Foot pain severity rating (0-10 Numeric 
rating scale) in the previous month 
a
 
0.29 (-0.27, 0.85) 0.46 (-0.21, 1.13) 
Rasch-transformed MFPDI pain score 0.02 (-0.28, 0.33) 0.37 (<-0.01, 0.74) 
Rasch-transformed MFPDI function score 0.00 (-0.31, 0.31) 0.27 (-0.11, 0.65) 
SF-12 PCS score -1.04 (-2.96, 0.88) 0.69 (-3.11, 1.73) 
SF-12 MCS score -0.49 (-2.57, 1.59) -0.69 (-3.32, 1.94) 
HADS anxiety score -0.08 (-0.76, 0.60) -0.16 (-0.96, 0.65) 
HADS depression score -0.06 (-0.60, 0.49) 0.20 (-0.46, 0.86) 
 Adjusted 
e
 OR (95% CI)
 
Adjusted
 e
 OR (95% CI) 
Frequent foot pain in the previous month 
b 
0.94 (0.57, 1.56) 1.43 (0.79, 2.59) 
Dissatisfaction with foot symptoms 
c 
0.64 (0.38, 1.09) 1.00 (0.55, 1.82) 
Bilateral hallux valgus 
d 
1.45 (0.75, 2.81) 1.26 (0.58, 2.72) 
Unilateral hallux valgus 
d
 – left foot 2.96 (1.23, 7.12) 2.18 (0.76, 6.30) 
Unilateral hallux valgus 
d
 – right foot 0.67 (0.30, 1.52) 0.77 (0.31, 1.95) 
Hip pain in the previous year 0.84 (0.48, 1.49) 0.94 (0.46, 1.93) 
Knee pain in the previous year 0.82 (0.43, 1.60) 1.55 (0.67, 3.59) 
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Table 3 Descriptive and symptomatic outcomes analysed using only 18-month data.   
MTPJ= metatarsophalangeal joint; OA= osteoarthritis; 
a
 Services or treatment for foot pain included at least one 
of the following: physiotherapy, hospital specialist, podiatrist, chiropodist, acupuncture, osteopath or chiropractor, 
drugs on prescription, foot operation, foot injection, or general practitioner (family doctor); 
b
 Not calculated as 
expected cell counts below five for all three phenotypes. 
 
      
                                                                                                                                                                    
 
 
 
 
 
No or minimal 
foot OA 
Isolated first 
MTPJ OA 
Polyarticular 
foot OA 
P-value 
Perceived global 
change in foot 
pain in previous 
18 months: n (%) 
Improved 95 (31.6) 26 (26.0) 13 (18.8) 
0.108 Unchanged 122 (40.5) 47 (47.0) 28 (40.6) 
Deteriorated 84 (27.9) 27 (27.0) 28 (40.6) 
Foot injury in previous 18 months: n (%) 18 (6.2) 8 (8.1) 7 (10.8) 0.404 
Use of services or treatment for foot pain in 
previous 18 months 
a
: n (%) 
146 (48.5) 45 (45.5) 37 (54.4) 0.519 
Foot operation in previous 18 months: n 
(%) 
1 (0.3) 4 (4.0) 2 (2.9) 
b 
